Immix Biopharma (IMMX) today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. A Key Opinion Leader (KOL) event to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results